ERBB2 and non-small cell lung carcinoma: To determine the appropriate treatment strategy, prior sequencing of oncogenic driver mutations for NSCLC, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), Kirsten rat sarcoma viral oncogene homolog (KRAS), c-ros oncogene 1 (ROS1), mesenchymal–epithelial transition (MET), human epidermal growth factor receptor 2 (HER2), v-raf murine sarcoma viral oncogene homolog B (BRAF), ret proto-oncogene (RET), and neurotrophic tyrosine receptor kinase, is strongly recommended [5].